Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016', provides in depth analysis on Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted pipeline therapeutics. The report provides comprehensive information on the Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - The report reviews Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics and enlists all their major and minor projects - The report assesses Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) Overview 9 Therapeutics Development 10 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Stage of Development 10 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Therapy Area 11 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Indication 12 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Companies 17 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Universities/Institutes 20 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Therapeutics Assessment 22 Assessment by Monotherapy/Combination Products 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 26 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Companies Involved in Therapeutics Development 27 Connexios Life Sciences Pvt. Ltd. 27 CymaBay Therapeutics, Inc. 28 Genfit SA 29 GlaxoSmithKline Plc 30 Inventiva 31 Mitobridge, Inc. 32 Nippon Chemiphar Co., Ltd. 33 Plexxikon Inc. 34 T3D Therapeutics, Inc. 35 vTv Therapeutics LLC 36 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Drug Profiles 37 CNX-013B2 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 elafibranor - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 GW-610742 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 HPP-593 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 IVA-337 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 MBX-8025 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 NC-2400 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Target PPAR delta for Mitochondrial Diseases - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 T3D-959 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Dormant Projects 62 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Discontinued Products 65 Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Featured News & Press Releases 66 Mar 31, 2016: GENFIT to Begin Elafibranor Clinical Program in PBC 66 Mar 30, 2016: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases 66 Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia 68 Mar 10, 2016: GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH 69 Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress 70 Feb 11, 2016: Data from phase 2b trial of Genfit elafibranor published in Gastroenterology 71 Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge 73 Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input 74 Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis 76 Jun 22, 2015: T3D Therapeutics Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients 76 Jun 08, 2015: T3D Therapeutics Selected by the Alzheimer's Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer's Association International Conference 77 Apr 24, 2015: New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion 77 Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia 79 Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 79 Mar 26, 2015: Genfit Announces Topline Results From The Golden-505 Trial In Nash 80 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 8
List of Tables
Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Indication, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Products under Investigation by Universities/Institutes, H1 2016 21 Assessment by Monotherapy/Combination Products, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 26 Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 27 Pipeline by CymaBay Therapeutics, Inc., H1 2016 28 Pipeline by Genfit SA, H1 2016 29 Pipeline by GlaxoSmithKline Plc, H1 2016 30 Pipeline by Inventiva, H1 2016 31 Pipeline by Mitobridge, Inc., H1 2016 32 Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 33 Pipeline by Plexxikon Inc., H1 2016 34 Pipeline by T3D Therapeutics, Inc., H1 2016 35 Pipeline by vTv Therapeutics LLC, H1 2016 36 Dormant Projects, H1 2016 62 Dormant Projects (Contd..1), H1 2016 63 Dormant Projects (Contd..2), H1 2016 64 Discontinued Products, H1 2016 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
